Previous 10 | Next 10 |
REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermedi...
2023-04-12 08:19:28 ET TESSCO Technologies ( TESS ) +87% t echnologies to be acquired for $9.00 per share, valued at ~$161.4M. Altamira Therapeutics ( CYTO ) +70% . Triton International ( TRTN ) +31% i nfrastructure to buy Triton in $13.3B...
REDWOOD CITY, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermedi...
REDWOOD CITY, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk ...
2023-03-23 08:17:04 ET Jasper Therapeutics ( NASDAQ: JSPR ) has announced the appointment of Daniel Adelman, M.D., as the company’s Acting Chief Medical Officer. Previously Dr. Adelman served as Vice President of Clinical Operations and Biometrics at Pharm...
REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermedi...
2023-03-16 14:14:56 ET The following slide deck was published by Jasper Therapeutics, Inc. in conjunction with this event. For further details see: Jasper Therapeutics (JSPR) Investor Presentation - Slideshow
2023-03-08 17:57:13 ET Jasper Therapeutics press release ( NASDAQ: JSPR ): Q4 GAAP EPS of -$0.36 beats by $0.01 . Cash and cash equivalents as of December 31, 2022 were $38.3 million. With proceeds from its January 2023 public offering and sales through the at-the-mark...
Announced Expansion of Briquilimab (formerly known as JSP191) Development Strategy to Include Chronic Spontaneous Urticaria Presentation of Key Briquilimab Clinical Data, Including Initial Results in Stem Cell Transplant for Sickle Cell Disease and One Year Follow-Up for Acute Myeloid Leuke...
2023-03-07 11:35:38 ET Jerome Powell takes center stage today and tomorrow with his semiannual testimony. While it has brought plenty of volatility to the stock market, some asset classes are generally experiencing a bit more as a result. I’m talking about penny stocks and there ...
News, Short Squeeze, Breakout and More Instantly...
Jasper Therapeutics Inc. Company Name:
JSPR Stock Symbol:
NASDAQ Market:
Jasper Therapeutics Inc. Website:
REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneou...
REDWOOD CITY, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CS...
2024-06-16 16:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...